Ruben Mesa, MD, UT Health San Antonio Cancer Center

home / authors / ruben-mesa-md-ut-health-san-antonio

Articles

Ruben A. Mesa, MD

Dr. Mesa on the Rationale for the MOMENTUM Trial in Myelofibrosis

Ruben Mesa, MD, UT Health San Antonio Cancer Center
March 31st 2022

Ruben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.

Read More

Ruben A. Mesa, MD

Dr. Mesa on the Unique Characteristics of Momelotinib in Myelofibrosis

Ruben Mesa, MD, UT Health San Antonio Cancer Center
January 26th 2022

Ruben A. Mesa, MD, discusses the unique characteristics of momelotinib in myelofibrosis.

Read More

Rapid Readouts: SIMPLIFY-1 and SIMPLIFY-2 Trials

Rapid Readouts: SIMPLIFY-1 and SIMPLIFY-2 Trials

Ruben Mesa, MD, UT Health San Antonio Cancer Center
July 8th 2021

Ruben Mesa, MD, Director of UT Health San Antonio MD Anderson Cancer Center, presents data from the 2021 European Hematology Association Virtual Congress from the SIMPLIFY-1 and SIMPLIFY-2 trials of patients with myelofibrosis who were treated with momelotinib.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data